Tuberculosis: past and present
DOI:
https://doi.org/10.52692/1857-0011.2023.3-77.41Keywords:
tuberculosis, control, epidemiology, bacterial resistance, historical evolution, advancements, strategiesAbstract
Tuberculosis is a serious infectious disease with a global impact, causing a significant number of deaths each year. It continues to pose a major challenge to the healthcare system and requires sustained efforts for control and prevention. The aim of this study was to analyze the historical aspects of tuberculosis and the outcomes of global and local control programs. The materials and methods involved research of specialized literature. The main conclusions include the historical evolution of tuberculosis, the impact of discoveries and medical advancements on its treatment and control, as well as the ongoing need to implement effective prevention and treatment strategies.
References
Migliori G.B. Tuberculosis: The Essentials. Fourth Edition. European Respiratory Review, 2011; 20 (120) 125.
Paulson T. Epidemiology: A mortal foe. Nature 502, S2–S3 2013.
Huang F., Zhao Y. Global Control of Tuberculosis: Current Status and Future Prospects. Zoonoses. 2022; Vol. 2(1).
Migliori, G. B., & Raviglione, M. C. (Eds.). Essential Tuberculosis. 2021;
Raviglione M. C. Tuberculosis: The Essentials, Fourth Edition (Lung Biology in Health and Disease) 4th Edition. 2009;
World Health Organization. Communicable Diseases Cluster. (1999). What is DOTS? : a guide to understanding the WHO-recommended TB control strategy known as DOTS. World Health Organization. https:// apps.who.int/iris/handle/10665/65979
Stop TB Initiative & Stop TB Partnership. (2002). The global plan to stop tuberculosis : Stop TB Partnership. World Health Organization. https://apps.who.int/iris/ handle/10665/67355
Stop TB Partnership & World Health Organization. (2006). The global plan to stop TB, 2006-2015 / Stop TB Partnership. World Health Organization. https://apps.who.int/iris/handle/10665/43404
Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018 Apr;6(4):299-314.
Bjerrum S., Schiller I., Dendukuri N. et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev; 2019.
Kraef C, Yedilbayev A, Seguy N, et al. Uptake of the lateral flow urine LAM test in Europe and Central Asia. Int J Tuberc Lung Dis. 2022 Sep 1;26(9):835-841.
Yang C., Sobkowiak B., Naidu V., et al. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLoS Med; 19. 2022.
Vesga J.F., Hallett T.B., Reid M.J.A., et al., Arinaminpathy N. Assessing tuberculosis control priorities in high-burden settings: a modelling approach. Lancet Glob Heal 2019; 7: e585–e595
Afanasiev E.I., Russkikh O.E. Современные тенденции в эпидемиологии туберкулеза и ВИЧ-инфекции в мире и в Российской Федерации. RMJ. 2021;3:24–26.
Barberis I, Bragazzi NL, Galluzzo L., The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg. 2017;58(1):E9-E12.
Barbier M, Wirth T. 2016. The evolutionary history,demography, and spread of the Mycobacterium tuberculosis complex. Microbiol Spectrum 4(4):TBTB2-00082016. doi:10.1128/microbiolspec.TBTB2-0008-2016.
MALIK, Alina. The impact of the molecular genetic test on the diagnosis delay and outcome in patients with pulmonary tuberculosis. In: Moldovan Medical Journal, 2018, nr. 3(61), pp. 3-9.
Chesov D., Crudu V., Soltan V., Botnaru V. Reduction in treatment delay of MDR-TB cases as a result of Xpertt MTB/RIF implementation in Moldova. int j tuberc lung dis 2016; 20: S521.
Syunyakova D.A. особенности эпидемиологии туберкулеза в мире и в россии в период 2015-2020 гг. аналитический ОБЗОР Social’nye aspekty zdorov’a naselenia / Social aspects of population health [serial online] 2021; 67(3):11.
Trajman A, Felker I, Alves LC, et al., The COVID-19 and TB syndemic: the way forward. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):710-719.
Oancea C. et al. Tratat de pneumologie pentru medicii rezidenți, www.umft.ro/editura (2021).
Houben RMGJ, Dodd PJ The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. 2016; PLoSMed13(10):e1002152.
Menzies N., Swartwood N.; Testa C., et al., Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2021; 32(1):p 70-78.
WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2023 – 2021 data. Stockholm: European Centre for Disease Prevention and Control and Copenhagen: WHO Regional Office for Europe. 2023.
Global tuberculosis report 2022. Geneva: World Health organization; 2022. licence: cc bY-Nc-sa 3.0 iGo.
Shariq M, Sheikh JA, Quadir N, et al., COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respir Rev. 2022 Apr 13;31(164):210264.
Mondoni M, Saderi L, Sotgiu G. Novel treatments in multidrug-resistant tuberculosis. Curr Opin Pharmacol. 2021 Aug;59:103-115.
Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med. 2021 Dec 9;385(24):2271-2280.
Hamada Y, Getahun H, Tadesse BT, et al., HIV-associated tuberculosis. Int J STD AIDS. 2021 Aug;32(9):780-790.
Sultana ZZ, Hoque FU, Beyene J, et al., A. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jan 11;21(1):51. doi: 10.1186/s12879-020-05749-2. Erratum in: BMC Infect Dis. 2021 Jan 20;21(1):86.
Downloads
Published
License
Copyright (c) 2024 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
